Cubist/Calixa Deal the Latest in a String of Biotech Buyouts

Cubist Pharmaceuticals has announced plans to acquire tiny San Diego biotech Calixa Therapeutics for up to $402.5 million. The deal gives Cubist possession of an antibiotic that Calixa has been developing for complicated urinary tract and intra-abdominal infections. Cubist, based in Lexington, Mass., has...

[Company Profile] MicroPhage

People typically go into the hospital to get better, but many patients wind up sicker than when they came in. Hospital acquired infections (HAIs) such as Staphylococcus aureus (“staph”) can be deadly to patients with already weakened immune systems. Approximately 60 percent of patients with S. aureus...

ThromboGenics Starts Phase II Trial for Macular Degeneration Therapy

ThromboGenics, a company specializing in biotherapeutics for vascular diseases, cancer, and eye diseases, has announced the start of a Phase II trial of microplasmin to treat age-related wet macular degeneration (AMD). Wet AMD occurs when abnormal blood vessels behind the retina begin to grow under the...

Cytori’s (NASDAQ: CYTX) Natural Celution for Breast Reconstruction

By Mike Havrilla, ProActive Newsroom Cytori Therapeutics (NASDAQ: CYTX) is a leading global innovator in the emerging field of regenerative medicine using adipose (fat) tissue as a rich source of adult stem cells capable of differentiating into a variety of cell types. The Company develops and markets cell...

[Company Profile] Stentys

When treating an acute myocardial infarction, otherwise known as a heart attack, cardiologists typically install a drug-eluting stent in the blocked artery to open up the vessel and restore blood flow to the heart. However, cardiologists face a difficult decision when choosing the correct size stent....

Bioguard Wound Dressings Beat Swine Flu In Independent Study

It’s common knowledge that H1N1, the virus that causes swine flu, can be transmitted from person to person by coughing or sneezing. However, most people don’t realize that the simple act of changing a bandage may be enough to transmit the virus. Pathogens in a gauze dressing may become airborne...

Celgene Acquires Gloucester In $340M Deal

Biopharmaceutical company Celgene is plumping up its oncology pipeline with its latest acquisition. The Summit, NJ-based company has struck a deal to purchase Gloucester Pharmaceuticals for $340 million up front. Celgene has agreed to pay Gloucester an additional $300 million in future regulatory...

Vertex to Sell 1.5 Million Shares

Vertex Pharmaceuticals, a biotechnology company focused on the development and commercialization of small molecule drugs, has been busy raising cash to prepare for the launch of telaprevir to treat hepatitis C. The Cambridge, Mass.-based company announced plans to sell 11.5 million shares of common stock....